StreetInsider.com News Articles

Veru enrolls first patient in phase 2b trial for weight loss combination

Mon, 09 Mar 2026 08:31:12 -0400

Veru Inc. (NASDAQ: VERU) enrolled the first patient in its Phase 2b PLATEAU clinical trial testing enobosarm combined with semaglutide for weight loss in older patients with obesity, the company announced.

The double-blind, placebo-controlled study will evaluate approximately 200 patients aged 65 and older with a body mass index of at least 35 who are beginning semaglutide treatment. The trial aims to assess whether enobosarm, an oral selective androgen receptor modulator, can preserve lean muscle mass and physical function while enhancing fat loss when combined with semaglutide.

The primary endpoint measures percent change in total body weight at 68 weeks. An interim

Veru enrolls first patient in phase 2b trial for weight loss combination

Mon, 09 Mar 2026 08:31:12 -0400

The primary endpoint measures percent change in total body weight at 68 weeks. An interim

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mon, 09 Mar 2026 08:30:00 -0400

-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide --

-- Interim analysis expected in the first quarter calendar year 2027--

-- Final topline clinical data expected in the fourth quarter calendar year 2027--

MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases,

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mon, 09 Mar 2026 08:30:00 -0400

-- Interim analysis expected in the first quarter calendar year 2027--

-- Final topline clinical data expected in the fourth quarter calendar year 2027--

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mon, 09 Mar 2026 08:30:00 -0400

-- Interim analysis expected in the first quarter calendar year 2027--

-- Final topline clinical data expected in the fourth quarter calendar year 2027--

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mon, 09 Mar 2026 08:30:00 -0400

-- Interim analysis expected in the first quarter calendar year 2027--

-- Final topline clinical data expected in the fourth quarter calendar year 2027--

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 08:30:00 -0400

MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 pm – 3:50 pm ET.

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 08:30:00 -0400

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 08:30:00 -0400

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 08:30:00 -0400

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru

Form SCHEDULE 13G VERU INC. Filed by: Alyeska Investment Group, L.P.

Tue, 17 Feb 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260217/26014741.html

Form SCHEDULE 13G VERU INC. Filed by: Alyeska Investment Group, L.P.

Tue, 17 Feb 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260217/26014741.html

Form 10-Q VERU INC. For: Dec 31

Wed, 11 Feb 2026 10:32:00 -0400

si-local-file:///var/storage/secattach/20260211/25981231.html

Form 10-Q VERU INC. For: Dec 31

Wed, 11 Feb 2026 10:32:00 -0400

si-local-file:///var/storage/secattach/20260211/25981231.html

Veru, Inc. (VERU) reported Q1 EPS

Wed, 11 Feb 2026 07:36:07 -0400

Veru, Inc. (NASDAQ: VERU) reported Q1 EPS of ($0.26).

For earnings history and earnings-related data on Veru, Inc. (VERU) click here.

Form 8-K VERU INC. For: Feb 11

Wed, 11 Feb 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260211/25979174.html

Form 8-K VERU INC. For: Feb 11

Wed, 11 Feb 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260211/25979174.html

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Wed, 11 Feb 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter—

--Company to host conference call and webcast today at 8:00 a.m. ET--

MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update.

“The strategy for the next generation of obesity

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Wed, 11 Feb 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter—

--Company to host conference call and webcast today at 8:00 a.m. ET--

“The strategy for the next generation of obesity

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Wed, 11 Feb 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter—

--Company to host conference call and webcast today at 8:00 a.m. ET--

“The strategy for the next generation of obesity

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Wed, 11 Feb 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter—

--Company to host conference call and webcast today at 8:00 a.m. ET--

“The strategy for the next generation of obesity

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Wed, 04 Feb 2026 08:30:00 -0400

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update.

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Wed, 04 Feb 2026 08:30:00 -0400

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Wed, 04 Feb 2026 08:30:00 -0400

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Wed, 04 Feb 2026 08:30:00 -0400

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please